Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes

References

• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37–44.
   PubMed Web of Science ®Google Scholar
• Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16:624–9.
   PubMed Web of Science ®Google Scholar
• Christensen FH, Hansen T, Stankevicius E, Buus NH, Simonsen U. Elevated pressure selectively blunts flow-evoked vasodilatation in rat mesenteric small arteries. Br J Pharmacol 2007;150:80–7.
   PubMed Web of Science ®Google Scholar
• Ortiz PA, Garvin JL. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 2002;282:F777–F784.
   PubMed Web of Science ®Google Scholar
• Kurtz A. Renin release: sites, mechanisms, and control. Annu Rev Physiol 2011;73:377–99.
   PubMed Web of Science ®Google Scholar
• Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol 1996;270: F845–F851.
   PubMed Web of Science ®Google Scholar
• Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of nitric oxide inhibition on blood pressure and renal sodium handling: a dose-response study in healthy man. Clin Exp Hypertens 2012;34:567–74.
   PubMed Web of Science ®Google Scholar
• Bech JN, Nielsen EH, Pedersen RS, Svendsen KB, Pedersen EB. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension. Am J Hypertens 2007;20:287–95.
   PubMed Web of Science ®Google Scholar
• Mose FH, Larsen T, Bech JN, Pedersen EB. Effects of atorvastatin on systemic and renal nitric oxide in healthy man. Clin Exp Hypertens 2013;35:148–57.
   PubMed Web of Science ®Google Scholar
• Ott C, Schlaich MP, Schmidt BM, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008;196:704–11.
   PubMed Web of Science ®Google Scholar
• Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002;54:395–9.
   PubMed Web of Science ®Google Scholar
• John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005;149:473.
   PubMedGoogle Scholar
• Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de GK, Fliser D, Fauler G, Marz W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111: 2356–63.
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126–31.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J 2006;27:1182–90.
   PubMed Web of Science ®Google Scholar
• Balletshofer BM, Goebbel S, Rittig K, Enderle M, Schmolzer I, Wascher TC, Ferenc PA, Westermeier T, Petzinna D, Matthaei S, Haring HU. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes – a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes 2005;113:324–30.
   PubMed Web of Science ®Google Scholar
• Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 2005;65: 31–74.
   PubMed Web of Science ®Google Scholar
• Tran D, Lowy A, Howes JB, Howes LG. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes Obes Metab 2005;7:273–81.
   PubMed Web of Science ®Google Scholar
• Murrow JR, Sher S, Ali S, Uphoff I, Patel R, Porkert M, Le NA, Jones D, Quyyumi AA. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol 2012;6:42–9.
   PubMed Web of Science ®Google Scholar
• Procino G, Barbieri C, Carmosino M, Rizzo F, Valenti G, Svelto M. Lovastatin-induced cholesterol depletion affects both apical sorting and endocytosis of aquaporin-2 in renal cells. Am J Physiol Renal Physiol 2010;298:F266–F278.
   Google Scholar
• Procino G, Barbieri C, Carmosino M, Tamma G, Milano S, De BL, Mola MG, Lazo-Fernandez Y, Valenti G, Svelto M. Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. Pflugers Arch 2011; 462:753–66.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang Y, Bouley R, Chen Y, Matsuzaki T, Nunes P, Hasler U, Brown D, Lu HA. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Renal Physiol 2011;301: F309–F318.
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, Kim DS, Shin EK. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088–93.
   PubMed Web of Science ®Google Scholar
• Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980–7.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001;21:449–54.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010;11:2635–50.
   PubMed Web of Science ®Google Scholar
• Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007;49:792–8.
   PubMed Web of Science ®Google Scholar
• Pedersen EB, Danielsen H, Spencer ES. Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension. Eur J Clin Pharmacol 1984;26:543–7.
   PubMed Web of Science ®Google Scholar
• Pedersen EB, Eiskjaer H, Madsen B, Danielsen H, Egeblad M, Nielsen CB. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Nephrol Dial Transplant 1993;8:1064–70.
   PubMed Web of Science ®Google Scholar
• Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol 2001;280:F860–F867.
   PubMed Web of Science ®Google Scholar
• Graffe CC, Bech JN, Pedersen EB. Effect of high and low sodium intake on urinary aquaporin-2 excretion in healthy humans. Am J Physiol Renal Physiol 2012;302: F264–F275.
   PubMed Web of Science ®Google Scholar
• Matthesen SK, Larsen T, Lauridsen TG, Vase H, Gjorup PH, Nykjaer KM, Nielsen S, Pedersen EB. Effect of amiloride and spironolactone on renal tubular function, ambulatory blood pressure, and pulse wave velocity in healthy participants in a double-blinded, randomized, placebo-controlled, crossover trial. Clin Exp Hypertens 2012;34:588–600.
   PubMed Web of Science ®Google Scholar
• Hager H, Kwon TH, Vinnikova AK, Masilamani S, Brooks HL, Frokiaer J, Knepper MA, Nielsen S. Immunocytochemical and immunoelectron microscopic localization of alpha-, beta-, and gamma-ENaC in rat kidney. Am J Physiol Renal Physiol 2001;280:F1093–F1106.
   PubMed Web of Science ®Google Scholar
• van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001;52: 299–305.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Saito Y, Ohyama Y, Uchiyama T, Sumino H, Kurabayashi M. Effect of cerivastatin on endothelial dysfunction and aortic CD36 expression in diabetic hyperlipidemic rats. Hypertens Res 2004;27:589–98.
   Google Scholar
• Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, Nagai R, Kitamura T, Hirata Y. Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Heart Circ Physiol 2005;288:H1770–H1776.
   Web of Science ®Google Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19: 257–67.
   PubMed Web of Science ®Google Scholar
• Garvin JL, Ortiz PA. The role of reactive oxygen species in the regulation of tubular function. Acta Physiol Scand 2003;179:225–32.
   PubMedGoogle Scholar
• Koksal M, Eren MA, Turan MN, Sabuncu T. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur J Intern Med 2011;22:249–53.
   PubMed Web of Science ®Google Scholar
• Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 2007;3:567–77.
   PubMedGoogle Scholar
• Kashlan OB, Kleyman TR. Epithelial Na(+) channel regulation by cytoplasmic and extracellular factors. Exp Cell Res 2012;318:1011–9.
   Google Scholar
• Klussmann E, Maric K, Rosenthal W. The mechanisms of aquaporin control in the renal collecting duct. Rev Physiol Biochem Pharmacol 2000;141:33–95.
   Google Scholar
• van der Linde NA, Sijbrands EJ, Boomsma F, van den Meiracker AH. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 2006;47:1125–30.
   PubMed Web of Science ®Google Scholar